Last reviewed · How we verify
LY2334737
At a glance
| Generic name | LY2334737 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (PHASE3)
- A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2334737 CI brief — competitive landscape report
- LY2334737 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI